+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Single-cell Sequencing Services and Technologies Market, 2020-2030

  • ID: 5215162
  • Report
  • September 2020
  • Region: Global
  • 220 Pages
  • Roots Analysis

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 10x Genomics
  • Celldom
  • Fluidigm
  • LMU University Hospital
  • Petri
  • SingulOmics

Overview

Over the years, technological advances in the field of genomics have enabled pharma companies to adopt a more personalized and targeted approach to drug/therapy development. Specifically, next-generation sequencing (NGS) technologies have enabled millions of human genomes across diverse ethnicities, to be sequenced. The large volumes of genomic data from the aforementioned sequencing studies have led to the generation of valuable insights on individuals' likely responses to different treatment regimens. Innovation in this field have made NGS technologies increasingly affordable and accessible. In fact, the cost of sequencing a single genome has dropped from USD ~3 billion (Human Genome Project 1990) to USD 1,000 (Illumina sequencing kits) over the last two decades. However, NGS based analyses are limited to offering averaged insights on gene expression. In other words, this method is incapable of quantifying nucleic acid content in individual cells, and thereby, offering gene expression information at single cell resolution. To better understand the interactions of individual cells with their microenvironment, advanced molecular probing solutions are required. In this context, high-throughput single-cell analysis, an emerging analytical technique, is considered a powerful means for studying individual cells, enabling researchers to study gene expression at single cell resolution.

Single-cell sequencing techniques offer many advantages over traditional genomic analyses, enabling the detection of complex and rare cell populations, and elucidating development trajectories of distinct cell lineages. Despite the potential to be used across diverse segments in biotechnology and medical research, this technique is still limited to early-stage research activities. This is primarily attributed to certain challenges associated with data processing and quality control. Further, the lack of versatile in silico tools is also considered among the major roadblocks to meaningful analysis and interpretation of single cell sequencing data. Additionally, the high cost of process execution and affiliated labor intensive protocols are other barriers to the adoption of since-cell sequencing technology.  However, the introduction of the RNA-QC-Chain tool in 2018 (an effort to address the data processing and quality control related challenges) and the Human Cell Atlas project (responsible for developing the first whole transcriptome map of human cells), are considered prominent milestones in the field of single cell genomics. Presently, experts believe that the single-cell genomics market in North America, may reach USD 5 billion by 2025. Given, the potential of single-cell RNA sequencing (scRNA-seq) technologies to probe into previously unelucidated cellular mechanisms, and identify novel biomarkers/therapeutic targets, they are likely to witness significant adoption in biomedical research over the next decade.

Scope Of the Report

The ‘Single-cell Sequencing Services and Technologies Market, 2020-2030’ report features an extensive study of the current landscape and the future opportunities associated with single-cell sequencing services/technologies.

In addition to other elements, the report features:

  • An overview of the competitive landscape of single-cell sequencing service providers providing information on a number of parameters, such as year of establishment, company size, geographical location, sequencing method used (DNA sequencing, RNA sequencing, ATAC sequencing and DNA methylation), types of services offered (library preparation, sequencing and bioinformatics), type of library preparation system used and type of sequencing system used.
  • A detailed review of the competitive market landscape of single-cell sequencing workflow instruments providing information on a number of relevant parameters, such as target nucleic acid (DNA, RNA and protein), type of application (cell isolation, cDNA amplification and library preparation) and throughput. In addition, the report features competitive market landscape of single-cell sequencing systems providing information on parameters, such as type of application (single-cell, whole genome, whole exome and targeted sequencing), maximum output, maximum read length, system efficiency, sequencing chemistry (sequencing-by-synthesis, SMRT sequencing and nanopore sequencing). It also includes an analysis on the companies developing these systems, based on year of establishment, company size and geographical location.
  • An insightful competitiveness analysis of single-cell sequencing technologies based on relevant parameters, such as supplier power (based on a company’s employee count and years of experience) and other important technology related specifications, such as maximum sequencing output, maximum reads per run, maximum read length, quality score, applications and cost of sequencer.
  • Elaborate profiles of companies that are engaged in offering single-cell sequencing services and technologies. Each profile features a brief overview of the company, its financial information (if available), proprietary technology platform(s), recent developments and an informed future outlook.
  • An in-depth analysis of the various patents that have been filed/granted for single-cell sequencing technologies, based on parameters, such as patent type, publication year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus areas, and type of applicant, highlighting the leading industry/non-industry players (in terms of the size of intellectual property portfolio). It also features a patent benchmarking and valuation analysis.
  • A detailed analysis of the grants that have been awarded to research institutes engaged in projects related to single-cell sequencing, between 2016 and 2020, based on multiple parameters, such as year of grant award, grant amount, focus area, activity code, support period, funding mechanism, funding institute center, type of recipient organization, popular recipient organizations and prominent program officers.
  • An analysis of various developments/recent trends related to single-cell sequencing, offering insights on [A] partnerships and collaborations established within the industry, [B] funding and investments, and [C] recent product launches related to single-cell sequencing.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as number of single-cell samples sequenced annually, average cost of sequencing, and growth trends across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030. The chapter features the likely distribution of the opportunity across different [A] key market segments (services and technologies), [B] type of system (sequencing and workflow instruments), [C] end-user (pharmaceutical companies, academic and research institutions and other end-users), [D] area of application (diagnostics, drug discovery, precision medicine and others) and [E] geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading single-cell sequencing service and technology providers?
  • What are the recent developments in the single-cell sequencing domain?
  • Which organizations have filed the maximum number of patents in this field?
  • Which institutions have received the maximum grant funding?
  • What factors are likely to influence the evolution of this upcoming market?
  • How is the current and future opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 10x Genomics
  • Celldom
  • Fluidigm
  • LMU University Hospital
  • Petri
  • SingulOmics

1. PREFACE
1.1. Scope of the Report
1.2. Research and Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Single-Cell Sequencing
3.2.1. Comparison of Bulk RNA and Single-cell RNA Sequencing
3.3. Applications of Single-cell Sequencing
3.3.1. In Cancer Research
3.3.2. In Clinical Diagnostics
3.3.3. In Drug Discovery
3.3.4. In Embryology
3.3.5. In Immunology
3.3.6. In Microbiology
3.3.7. In Neurology
3.3.8. In Organ Development
3.4. Challenges Associated with Single-cell Sequencing
3.4.1. Data Pre-processing
3.4.2. Low Capturing Efficiency
3.4.3. Rigid and Undefined Statistical Frameworks
3.4.4. Lack of Appropriate Quality Control Systems
3.5. Future Perspectives

4. MARKET LANDSCAPE: SINGLE-CELL SEQUENCING SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Single-cell Sequencing Service Providers: Market Landscape of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Sequencing Method Used
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Type of Library Preparation System Used
4.2.7. Analysis by Type of Sequencing System Used
4.3. Single-cell Sequencing Service Providers: Market Landscape of Non-Industry Players
4.3.1. Analysis by Location of Organization
4.3.2. Analysis by Sequencing Method Used
4.3.3. Analysis by Type of Service Offered
4.3.4. Analysis by Type of Library Preparation System Used
4.3.5. Analysis by Type of Sequencing System Used

5. MARKET LANDSCAPE: SINGLE-CELL SEQUENCING TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Single-cell Sequencing Systems and Technologies: Market Landscape of Workflow Instruments
5.2.1. Analysis by Target Nucleic Acid
5.2.2. Analysis by Type of Application
5.2.3. Analysis by Throughput
5.3. Single-cell Sequencing Systems and Technologies: Developer Landscape
5.3.4. Analysis by Year of Establishment
5.3.5. Analysis by Company Size
5.3.6. Analysis by Location of Headquarters
5.4. Single-cell Sequencing Systems and Technologies: Market Landscape of Sequencing Instruments
5.4.1. Analysis by Type of Application
5.4.2. Analysis by Maximum Output
5.4.3. Analysis by Maximum Read Length
5.4.4. Analysis by System Efficiency
5.4.5. Analysis by Sequencing Chemistry
5.5. Single-cell Sequencing Systems and Technologies: Developer Landscape
5.5.6. Analysis by Year of Establishment
5.5.7. Analysis by Company Size
5.5.8. Analysis by Location of Headquarters

6. SINGLE-CELL SEQUENCING TECHNOLOGIES: COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Parameters and Methodology
6.3. Competitiveness Analysis: Single-cell Workflow Instruments
6.4. Competitiveness Analysis: Single-cell Sequencing Instruments

7. COMPANY PROFILES: SINGLE-CELL SEQUENCING SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Active Motif
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook
7.3. Admera Health
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook
7.4. Annoroad Genomics
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook
7.5. BGI Genomics
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook
7.6. CD Genomics
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook
7.7. MedGenome
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook
7.8. Quick Biology
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook
7.9. SingulOmics
7.9.1. Company Overview
7.9.2. Recent Developments and Future Outlook

8. COMPANY PROFILES: SINGLE CELL SEQUENCING TECHNOLOGY PROVIDERS
8.1. 10x Genomics
8.1.1. Company Overview
8.1.2. Financial Information
8.1.3. Product Portfolio
8.1.3.1. 10x Chromium
8.1.4. Recent Developments and Future Outlook
8.2. Cell Microsystems
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.2.1. Cellraft AIR
8.3. Fluidigm
8.3.1. Company Overview
8.3.2. Financial information
8.3.3. Product Portfolio
8.3.3.1. Fluidigm C1
8.3.4. Recent Developments and Future Outlook
8.4. Illumina
8.4.2. Financial Information
8.4.3. Product Portfolio
8.4.3.1. MiSeq Series
8.4.3.2. Nextseq Series
8.4.3.3. NovaSeq 6000 System
8.4.4. Recent Developments and Future Outlook
8.5. Mission Bio
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.2.1. Tapestri
8.5.3. Recent Developments and Future Outlook
8.6. Oxford Nanopore Technologies
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Product Portfolio
8.6.3.1. MinIon Systems
8.6.3.2. PromethIon Systems
8.6.4. Recent Developments and Future Outlook

9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Single-cell Sequencing: Patent Analysis
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Geographical Location
9.3.3. Analysis by CPC Symbols
9.3.4. Word Cloud: Emerging Focus Areas
9.3.5. Analysis by Type of Applicant
9.3.6. Leading Players: Analysis by Number of Patents
9.4. Single-cell Sequencing: Benchmarking Analysis
9.4.1. Analysis by Patent Characteristics
9.4.2. Analysis by Geography
9.5. Single-cell Sequencing: Patent Valuation Analysis

10. ACADEMIC GRANT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Single-cell Sequencing: Analysis of Academic Grants
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Grant Amount
10.3.3. Analysis by Focus Area
10.3.4. Analysis by Activity Code
10.3.5. Analysis by Support Period
10.3.6. Analysis by Funding Mechanism
10.3.7. Analysis by Funding Institute Center
10.3.8. Analysis by Type of Recipient Organization
10.3.9. Popular Recipient Organizations: Analysis by Number of Grants
10.3.10. Prominent Program Officers: Analysis by Number of Grants

11. RECENT DEVELOPMENTS: SINGLE-CELL SEQUENCING MARKET
11.1. Chapter Overview
11.2. Single-cell Sequencing: Recent Partnerships
11.2.1. Partnership Models
11.2.2. Analysis by Year of Partnership
11.2.3. Analysis by Type of Agreement
11.2.4. Analysis by Focus Area of Partnership
11.2.5. Regional Analysis by Number of Partnerships
11.3. Single-cell Sequencing: Recent Funding and Investments
11.3.1. Analysis by Year of Funding
11.3.3. Analysis by Type of Funding
11.3.2. Analysis by Amount Invested
11.3.4. Most Active Players: Analysis by Amount Invested
11.3.5. Most Active Investors: Analysis by Number of Funding Instances
11.4. Single-cell Sequencing: Recent Product Launches
11.4.1. Analysis by Year of Product Launch
11.4.2. Analysis by Type of Product
11.4.3. Analysis by Focus Area
11.4.4. Most Active Players: Analysis by Number of Launches

12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Overall Single-cell Sequencing Services and Technologies Market Opportunity,
12.4. Single-cell Sequencing Services and Technologies Market Opportunity Across Key Market Segments, 2020-2030
12.5. Single-cell Sequencing Services and Technologies Market Opportunity:
12.6. Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by End-User 2020 and 2030
12.7. Single-cell Sequencing Services and Technologies Market Opportunity: Distribution by Area of Application, 2020 and 2030
12.8. Single-cell Sequencing Services and Technologies Market Opportunity: Geographical Distribution, 2020 and 2030
12.8.1. Single-cell Sequencing Services and Technologies Market Opportunity in North America, 2020-2030
12.8.1.1. Single-cell Sequencing Services and Technologies Market Opportunity in North America Across Key Market Segments, 2020-2030
12.8.1.1.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Service Providers, 2020-2030
12.8.1.1.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Technology Providers, 2020-2030
12.8.1.2. Single-cell Sequencing Services and Technologies Market Opportunity in North America: Distribution by End-Users, 2020-2030
12.8.1.2.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Academic and Research Institutions, 2020-2030
12.8.1.2.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Pharmaceutical Companies, 2020-2030
12.8.1.2.3. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other End-Users, 2020-2030
12.8.1.3. Single-cell Sequencing Services and Technologies Market Opportunity in North America: Distribution by Area of Application, 2020-2030
12.8.1.3.1. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Diagnostics, 2020-2030
12.8.1.3.2. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Drug Discovery, 2020-2030
12.8.1.3.3. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Precision Medicine, 2020-2030
12.8.1.3.4. Single-cell Sequencing services and Technologies Market Opportunity in North America: Share of Other Applications, 2020-2030
12.8.2. Single-cell Sequencing Services and Technologies Market Opportunity in Europe, 2020-2030
12.8.2.1. Single-cell Sequencing Services and Technologies Market Opportunity in Europe Across Key Market Segments, 2020-2030
12.8.2.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Service Providers, 2020-2030
12.8.2.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Technology Providers, 2020-2030
12.8.2.2. Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Distribution by End-Users, 2020-2030
12.8.2.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Academic and Research Institutions, 2020-2030
12.8.2.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Pharmaceutical Companies, 2020-2030
12.8.2.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other End-Users, 2020-2030
12.8.2.3. Single-cell Sequencing Services and Technologies Market Opportunity in Europe: Distribution by Area of Application, 2020-2030
12.8.2.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Diagnostics, 2020-2030
12.8.2.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Drug Discovery, 2020-2030
12.8.2.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Precision Medicine, 2020-2030
12.8.2.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Europe: Share of Other Applications, 2020-2030
12.8.3. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific, 2020-2030
12.8.3.1. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific Across Key Market Segments, 2020-2030
12.8.3.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Service Providers, 2020-2030
12.8.3.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Technology Providers, 2020-2030
12.8.3.2. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Distribution by End-Users, 2020-2030
12.8.3.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030
12.8.3.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030
12.8.3.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other End-Users, 2020-2030
12.8.3.3. Single-cell Sequencing Services and Technologies Market Opportunity in Asia-Pacific: Distribution by Area of Application, 2020-2030
12.8.3.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Diagnostics, 2020-2030
12.8.3.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Drug Discovery, 2020-2030
12.8.3.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Precision Medicine, 2020-2030
12.8.3.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Asia-Pacific: Share of Other Applications, 2020-2030
12.8.4. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World, 2020-2030
12.8.4.1. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World Across Key Market Segments, 2020-2030
12.8.4.1.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Service Providers, 2020-2030
12.8.4.1.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Technology Providers, 2020-2030
12.8.4.2. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Distribution by End-Users, 2020-2030
12.8.4.2.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Academic and Research Institutions, 2020-2030
12.8.4.2.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Pharmaceutical Companies, 2020-2030
12.8.4.2.3. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other End-Users, 2020-2030
12.8.4.3. Single-cell Sequencing Services and Technologies Market Opportunity in Rest of the World: Distribution by Area of Application, 2020-2030
12.8.4.3.1. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Diagnostics, 2020-2030
12.8.4.3.2. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Drug Discovery, 2020-2030
12.8.4.3.3. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Precision Medicine, 2020-2030
12.8.4.3.4. Single-cell Sequencing services and Technologies Market Opportunity in Rest of the World: Share of Other Applications, 2020-2030

13. CONCLUSION
13.1. Chapter Overview
13.2. Key Takeaways

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Genuity Science
14.2.1. Company Snapshot
14.2.2. Interview Transcript, Irene Blat, Senior Director of Data Products and Analytics

Note: Product cover images may vary from those shown
  • 10x Genomics
  • 1CellBio
  • Active Motif
  • Admera Health
  • Aelian Biotechnology
  • Agency for Science Technology and Research
  • Agilent Technologies
  • Albert Einstein College of Medicine
  • Annoroad Gene Technology
  • Australian Genome Research Facility
  • Becton Dickinson
  • BGI Genomics
  • Bigelow Single Cell Genomics Centre
  • Bioinformatics and Expression Analysis Core Facility (Karolinska Institutet)
  • BioLegend
  • Immudex
  • Biomedical Research Core Facilities (University of Michigan Medical School)
  • Biopolymers Facility (Harvard Medical School)
  • Bio-Rad Laboratories
  • Biotech Research and Innovation Centre (University of Copenhagen)
  • Biotechnology Center (University of Wisconsin-Madison)
  • Broad Institute
  • Bucher Biotec
  • California Institute of Technology
  • Cancer Genomics Center (University of Texas)
  • Cancer Research UK Cambridge Institute (University of Cambridge)
  • CARTANA
  • CD Genomics
  • Cedars-Sinai Genomics Core
  • Cell Biologics
  • Cell Microsystems
  • Cellarity
  • CellChorus
  • Celldom
  • CellTool
  • Cellular Research
  • Celsee
  • Celsius Therapeutics
  • Center for Gastrointestinal Biology and Disease (University of North Carolina School of Medicine)
  • Center for Genetic Medicine (Northwestern University)
  • Center for Translational Genomics (Lund University)
  • Centre for Genome-Enabled Biology and Medicine (University of Aberdeen)
  • Centre for Health Genomics and Informatics (University of Calgary)
  • Centro Nacional de Análisis Genómico
  • Clearbridge BioMedics
  • Cleveland Clinic
  • Cold Spring Harbor Laboratory
  • Columbia Genome Center (Columbia University)
  • Core Facility Genomics (Amsterdam UMC)
  • Core Immunology Lab (University of California)
  • Covance
  • Cytena
  • Cytomos
  • Cytosurge
  • DNA Core Facility (University of Missouri)
  • DNA Technologies Core (University of California Davis)
  • Dolomite Bio
  • Droplet Genomics
  • Duke Molecular Physiology Institute
  • Earlham Institute
  • Eldan
  • Enigma Life Sciences
  • Epigenomics and DNA Sequencing Core Facility (NIH)
  • Epinomics
  • Exosomeplus
  • FlowJo
  • Fluidigm
  • Fulgent Genetics
  • Functional Genomics Center Zurich (University of Zurich)
  • GenapSys
  • Genentech
  • Genetic Resources Core Facility (Johns Hopkins University)
  • GENEWIZ
  • Genome Quebec
  • Genome Sequencing Service Center (Stanford University)
  • Genome Technology Access Center (Washington University)
  • GenomeScan
  • Genomics Core Facility (European Molecular Biology Laboratory)
  • Genomics Core Facility (Lewis-Sigler Institute for Integrative Genomics)
  • Genomics Facility (University of Chicago)
  • Genuity Science
  • Gladstone Genomics Core
  • Hangzhou Chengyuan Genomics
  • Harvard College
  • Harvard University
  • Huntsman Cancer Institute (University of Utah)
  • Illumina
  • Imperial BRC Genomics Facility (Imperial College London)
  • Imperial Life Sciences
  • InCellDx
  • Indiana University School of Medicine (Indiana University)
  • Institute for Genome Sciences (University of Maryland School of Medicine)
  • Institute for Molecular Bioscience (University of Queensland)
  • Intermountain Healthcare
  • Iowa Institute of Human Genetics (University of Iowa)
  • IsoPlexis
  • Johnson & Johnson
  • Katholieke Universiteit Leuven
  • Kinghorn Medical Center (Garvan-Weizmann Medical Center)
  • LC Sciences
  • LMU University Hospital
  • LumaCyte
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • University of Texas MD Anderson Cancer Center
  • MedGenome
  • MGI
  • MilliporeSigma
  • Minos Biosciences
  • Mission Bio
  • Monash Health Translation Product Medical Genomics Facility
  • NanoString Technologies
  • Nashville Biosciences
  • Natera
  • NeuroInDx
  • nference
  • Novogene
  • Nucleome Informatics
  • NXTGNT (Ghent University)
  • OICR Genomics and Bioinformatics
  • Onconova Therapeutics
  • Ottawa Hospital Research Institute
  • Oxford Genetics (University of Edinburgh)
  • Oxford Genomics Centre (University of Oxford)
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Partek
  • Peak Analysis and Automation
  • Perelman School of Medicine (University of Pennsylvania)
  • PerkinElmer
  • Petri
  • Pittsburgh Liver Research Centre (University of Pittsburgh)
  • Princess Margaret Genomics Centre
  • Proteona
  • Psomagen
  • QB3 Genomics (University of California, Berkeley)
  • QIAGEN
  • Quick Biology
  • Ramaciotti Centre for Genomics
  • ReadCoor
  • Rockefeller University
  • RootPath
  • S2 Genomics
  • Saban Research Institute
  • Salk Institute of Biological Sciences
  • Sanford Burnham Prebys Medical Discovery Institute
  • Scailyte
  • SciLifeLab
  • Scipio Bioscience
  • Semel Institute for Neuroscience and Behavior (University of California)
  • SeqLL
  • SeqMatic
  • Sequencing Core Facility (Max Planck Institute for Molecular Genetics)
  • seqWell
  • Singleron Biotechnologies
  • Single Cell Analysis Facility (NCI Frederick Accessioning)
  • Single Cell Discoveries
  • Single Cell Genomics Core (Baylor College of Medicine)
  • Single Cell Genomics Core (Brigham and Women's Hospital)
  • Single Cell Sequencing Core - Department of Medicine (Boston University)
  • Singlera Genomics
  • SingulOmics
  • Spanish National Center for Cardiovascular Research
  • Spatial Transcriptomics
  • Sphere Fluidics
  • Split Bioscience
  • St. Jude Children's Research Hospital
  • Stanford University
  • Sylvester Comprehensive Cancer Center (University of Miami)
  • Takara Bio
  • Technology Center for Genetics and Bioinformatics (University of California)
  • Turku Bioscience (University of Turku)
  • University of Auckland
  • University of Buffalo Genomics and Bioinformatics Core
  • University of California
  • University of Helsinki
  • University of Kansas Medical Center
  • University of Oxford
  • University of Texas
  • UT Southwestern Medical Center (University of Texas)
  • Vanderbilt Technologies for Advanced Genomics
  • VIB Nucleomics Core (VIB)
  • VyCAP
  • WaferGen Bio-systems
  • Wellcome Sanger Institute
  • Wexner Medical Center (Ohio State University)
  • Wistar Institute
  • X Gen
  • Yale Center for Genome Analysis (Yale School of Medicine)
  • Yerkes National Primate Research Center (Emory University)
  • Zephyrus Biosciences
  • Zomedica Pharmaceuticals
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll